Form 4: Clene Director Matthew Kiernan Granted Stock Options
Insider Transaction Report
Clene Inc. Director Matthew Kiernan was granted 1,893 stock options with an exercise price of $7.30 per share, vesting immediately.
Summary
- Matthew Kiernan, a Director of Clene Inc. (CLNN), was granted stock options.
- The transaction date for this grant is reported as November 13, 2025.
- The grant consists of 1,893 options for common stock.
- Each option has an exercise price of $7.30 per share.
- These options vest immediately upon grant.
- The options expire on November 12, 2035.
- Following this transaction, Matthew Kiernan beneficially owns 1,893 derivative securities directly.
Sentiment
Score: 6
Explanation: Slightly positive, as the grant of stock options to a director generally aligns their interests with shareholders, though the future-dated transaction is an unusual reporting anomaly.
Positives
- The grant of stock options to a director, Matthew Kiernan, aligns his interests with those of shareholders, incentivizing long-term company performance.
- The options vest immediately upon grant, providing immediate equity exposure and a direct link to future stock performance.
Negatives
- The reported transaction date of November 13, 2025, is in the future, which is unusual for a Form 4 filing that typically reports completed transactions. This could indicate a clerical error in the filing.
Risks
- Potential for minor shareholder dilution if the options are exercised in the future, increasing the number of outstanding shares.
Future Outlook
The filing does not contain forward-looking statements or guidance beyond the terms of the stock option grant itself.
Industry Context
The grant of stock options is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and incentivize directors and key personnel by aligning their financial interests with the long-term success and shareholder value of the company.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation Plan Utilization | The stock options were granted under the Clene Inc. Amended 2020 Stock Plan, indicating adherence to an established equity compensation framework for directors and employees. | 11/13/2025 | Reinforces the company's existing compensation structure and its commitment to using equity-based incentives. |
Related Party Transactions
- The grant of stock options to Matthew Kiernan, a Director, constitutes a related party transaction as part of his compensation package.
Stakeholder Impact
- Shareholders: Potential for minor dilution upon future exercise of options; increased alignment of director's interests with shareholder value.
- Management/Employees: Reflects ongoing use of equity compensation plans to incentivize key personnel and directors.
Key Dates
| Date | Description |
|---|---|
| 11/14/2025 | Date the Form 4 was signed by Jerome T. Miraglia, POA for Matthew Kiernan. |
| 11/13/2025 | Date of earliest transaction (stock option grant date) and immediate vesting date. |
| 11/12/2035 | Expiration date of the granted stock options. |
Keywords
Clene Inc., CLNN, Matthew Kiernan, stock options, insider transaction, Form 4, director compensation, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.